biostudies-literatureBadr HNational Cancer InstituteNCI NIH HHSe7306https://www.ebi.ac.uk/biostudies/studies/S-EPMC11306290biostudies-literatureUnknown13(15)<h4>Purpose</h4>This study aimed to develop and validate FinTox, a concise tool for screening and managing financial toxicity in oncology settings.<h4>Methods</h4>Development involved qualitative interviews with healthcare providers and patients, and feedback from a 7-member expert panel resulting in a 5-item measure that evaluates financial strain, psychological responses, and care modifications. Psychometric evaluations examined factor structure, internal consistency, test-retest reliability, and concurrent and convergent validity. Associations between FinTox scores and sociodemographic/medical factors were also analyzed using univariate and multivariable regression models.<h4>Results</h4>Twelve healthcare providers and 20 patients were interviewed, and 268 patients (69.8% female, 47.4% Cancer medicineDevelopment and validation of FinTox: A new screening tool to assess cancer-related financial toxicity.PMC11306290P30 CA125123‐14S7P30 CA125123P30 CA125123-14S7Badr HHan JMims MfalseDevelopment and validation of FinTox: A new screening tool to assess cancer-related financial toxicity.<h4>Purpose</h4>This study aimed to develop and validate FinTox, a concise tool for screening and managing financial toxicity in oncology settings.<h4>Methods</h4>Development involved qualitative interviews with healthcare providers and patients, and feedback from a 7-member expert panel resulting in a 5-item measure that evaluates financial strain, psychological responses, and care modifications. Psychometric evaluations examined factor structure, internal consistency, test-retest reliability, and concurrent and convergent validity. Associations between FinTox scores and sociodemographic/medical factors were also analyzed using univariate and multivariable regression models.<h4>Results</h4>Twelve healthcare providers and 20 patients were interviewed, and 268 patients (69.8% female, 47.4% 2024-01-01T00:00:00Z2024 Aug2026-06-04T05:32:14.268Z2025-04-04T01:02:54.936ZS-EPMC113062903911322210.1002/cam4.7306